Shareholders Approve 200 Million Share Increase, Authorizing 147% Potential Dilution

summarizeSummary

Humacyte shareholders approved an amendment to increase authorized common stock by 200 million shares, raising the total to 550 million and creating potential for 147.72% dilution if fully utilized.

check_boxKey Events

• Authorized Share Increase Approved

  Stockholders approved an amendment to the Certificate of Incorporation, increasing the number of authorized common shares from 350,000,000 to 550,000,000. This amendment became effective on June 9, 2026.

• Significant Potential Dilution

  With 222,019,108 shares outstanding, the increase in authorized shares creates headroom for an additional 327,980,892 shares. If all authorized shares were issued, dilution would be 147.72%.

• Annual Meeting Results

  Shareholders also elected three Class II directors, approved named executive officer compensation on an advisory basis, set the frequency of future advisory votes on executive compensation to annual, and ratified Pricewaterhouse Coopers LLP as the independent auditor.

auto_awesomeAnalysis

Humacyte's stockholders approved an amendment to increase the authorized common stock from 350 million to 550 million shares. This 200 million share increase, now effective, significantly expands the company's capacity to issue new shares. With 222,019,108 shares currently outstanding, if all newly authorized shares were issued, it would result in a potential dilution of 147.72% for existing shareholders. This authorization follows previous dilutive equity raises and a 'going concern' warning, indicating the company is preparing for substantial future capital raises to support its operations.